Luis A. Diaz Jr, MD, head, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, discusses the recent FDA approval of pembrolizumab (Keytruda) for microsatellite instability-high (MSI-H) colorectal cancer and other tumor types.
SunRISE Program Incites Optimism About the Future of High-Risk, BCG-Unresponsive NMIBC Treatment
May 24th 2023In an interview with Targeted Oncology, Siamak Daneshmand, MD, discussed TAR-200 as seen in the SunRISE-1 trial and the what is up next for the treatment landscape of high-risk BCG-unresponsive non-muscle invasive bladder cancer.
Read More
FDA Grants Orphan Drug Designation to Mitazalimab for Pancreatic Cancer
May 23rd 2023Mitazalimab has received an orphan drug designation from the FDA and is currently being investigated in the OPTIMIZE-1 trial in combination with modified FOLFIRINOX for the treatment of patients with pancreatic cancer.
Read More
2 Clarke Drive
Cranbury, NJ 08512